UCB and Immunomedics announced on Friday top-line results from a Phase IIb clinical study which compared the effect of the drug candidate epratuzumab to placebo in people with systemic lupus. The data showed that the 12-week dose response and the dose frequency study of epratuzumab in patients with moderate to severe active lupus demonstrated a clinically meaningful treatment effect showing the drug was more effective than placebo in reducing symptoms of lupus.
“The LFA congratulates UCB and Immunomedics on the positive results from this clinical study of epratuzumab,” said Sandra C. Raymond, President & CEO of the Lupus Foundation of America. “We eagerly await the release of additional data from this mid-stage clinical study.”
“It has been 50 years since the U.S. Food and Drug Administration approved a new treatment for lupus,” said Raymond. “We are excited to see several promising new lupus therapies in the pipeline and we are encouraged that physicians may soon have new treatment options to manage this devastating and life-threatening disease.”
Read the full UCB Press Release.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment